RxDoctor Payments Data

Miguel Lizama, MD

Internal Medicine · Mission Hills, CANPI 1174699151

Payments from drug & device makers

$406in general payments, 2019–2025

Across 25 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$139
  • E.r. Squibb & Sons, L.L.C.$81
  • Sobi, Inc$64
  • Pfizer$36
  • Merck$32
  • Teva Pharmaceuticals USA, Inc.$17
  • plus $37 from 3 others

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$406 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$32,828
Medicare patients
105
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$150,393
OzempicSemaglutide86$119,300
TrulicityDulaglutide75$92,070
JardianceEmpagliflozin108$84,186
FarxigaDapagliflozin Propanediol68$44,190
EntrestoSacubitril/Valsartan26$28,770
RybelsusSemaglutide17$26,641
XareltoRivaroxaban12$17,458
LinzessLinaclotide13$14,787
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$13,805
Atorvastatin Calcium1,151$13,440
Combivent RespimatIpratropium/Albuterol Sulfate14$9,865
Humalog Kwikpen U-100Insulin Lispro42$9,503
MyrbetriqMirabegron16$8,546
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$150,393199 claims
Novo NordiskOzempic, Rybelsus$139$145,942103 claims
MerckDulera$32$6,26413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →